EpiCast Report: Alzheimer s Disease - Epidemiology Forecast to 2026

  • ID: 4429116
  • Drug Pipelines
  • 37 pages
  • GlobalData
1 of 3
EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

Summary

Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide.

To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) to diagnose dementia, and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria to diagnose AD.

In the 7MM, our epidemiologists forecast an increase in the total prevalent cases of AD from around 10.6 million total prevalent cases in 2016 to around 13.7 total prevalent cases in 2026, at an annual growth rate (AGR) of nearly 3% during the forecast period. Among the 7MM, the US will have the highest number of total prevalent cases of AD throughout the forecast period, while the UK will have the lowest.

Similarly, our epidemiologists forecast that the total prevalent cases of MCI in the 7MM will increase from over 28 million total prevalent cases in 2016 to around 34.5 million total prevalent cases in 2026 at an AGR of about 2%. Among the 7MM, the US will have the highest number of total prevalent cases of MCI throughout the forecast period, while Spain will have the lowest.

The report "EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for AD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the total prevalent cases of AD (diagnosed and undiagnosed) segmented by sex, age (ages 60 years and older), and severity in these markets. Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases of MCI segmented by sex and age (ages 60 years and older) in these markets.

Scope
  • The Alzheimer’s Disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AD (diagnosed and undiagnosed) segmented by sex, age (ages 60 years and older), and severity in these markets. Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age (ages 60 years and older) in these markets.
  • The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Alzheimer’s Disease EpiCast report will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global AD market.
  • Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
  • Understand severity of prevalent AD cases and total prevalent cases of MCI.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2 Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Total Prevalent Cases of AD
3.4.4 Total Prevalent Cases of AD by Severity
3.4.5 Total Prevalent Cases of MCI
3.5 Epidemiological Forecast for AD (2016-2026)
3.5.1 Total Prevalent Cases of AD
3.5.2 Age-Specific Total Prevalent Cases of AD
3.5.3 Sex-Specific Total Prevalent Cases of AD
3.5.4 Total Prevalent Cases of AD by Severity
3.6 Epidemiological Forecast for MCI (2016-2026)
3.6.1 Total Prevalent Cases of MCI
3.6.2 Age-Specific Total Prevalent Cases of MCI
3.6.3 Sex-Specific Total Prevalent Cases of MCI
3.7 Discussion
3.7.1 Epidemiological Forecast Insight
3.7.2 Limitations of Analysis
3.7.3 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About
4.4 Contact
4.5 Disclaimer

List of Tables
Table 1: DSM-IV Criteria for the Diagnosis of Dementia
Table 2: NINCDS-ADRDA Criteria for the Diagnosis of AD
Table 3: Risk Factors and Comorbidities for AD
Table 4: 7MM, Total Prevalent Cases of AD, Both Sexes, Ages =60 Years, Selected Years 2016-2026.
Table 5: 7MM, Total Prevalent Cases of MCI, Both Sexes, Ages =60 Years, Selected Years 2016-2026.

List of Figures
Figure 1: 7MM, Total Prevalent Cases of AD, Both Sexes, Ages =60 Years, 2016 and 2026
Figure 2: 7MM, Total Prevalent Cases of MCI, Both Sexes, Ages =60 Years , 2016 and 2026
Figure 3: 7MM, Age-Standardized Total Prevalence of AD (%), Ages =60 Years
Figure 4: 7MM, Age-Standardized Total Prevalence of MCI (%), Ages =60 Years
Figure 5: 7MM, Sources Used and Not Used, Total Prevalent Cases of AD
Figure 6: 7MM, Sources Used, Total Prevalent Cases of AD by Severity
Figure 7: 7MM, Sources Used, Total Prevalent Cases of MCI
Figure 8: 7MM, Age-Specific Total Prevalent Cases of AD, Both Sexes, 2016
Figure 9: 7MM, Sex-Specific Total Prevalent Cases of AD, Both Sexes, Ages >60 Years, 2016
Figure 10: 7MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages =60 Years, 2016
Figure 11: 7MM, Age-Specific Total Prevalent Cases of MCI, Both Sexes, 2016
Figure 12: 7MM, Sex-Specific Total Prevalent Cases of MCI, Both Sexes, Ages >60 Years, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll